Aurinia Pharmaceuticals (AUPH) has released an update.
Aurinia has completed its strategic review and is now set to initiate a stock buyback program, as revealed in their latest press release. This move signals confidence in the company’s value and offers a potential benefit to shareholders by possibly enhancing stock prices.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
